HOME JOURNALS CONTACT

Pakistan Journal of Biological Sciences

Year: 2010 | Volume: 13 | Issue: 18 | Page No.: 906-910
DOI: 10.3923/pjbs.2010.906.910
VKORC1 Gene Analysis of Some Iranian Sensitive Patients to Warfarin
Z. Kianmehr, P. Ghadam, S. Sadrai, B. Kazemi and R.A. Sharifian

Abstract: VKORC1 is a component of the enzyme that is the therapeutic target site of warfarin. In order to investigate the relationship between VKORC1 gene and warfarin dose response, we studied this gene in 22 clinically sensitive patients and 36 clinically normal patients as control group that in previous studies their blood warfarin levels were determined by HPLC and genotyped for CYP2C9. In the majority of these patients, the results had shown that the clinical phenotype was according to the CYP2C9 genotype, but there were sensitive patients with normal CYP2C9 genotype. So in this study for investigation of another reason of sensitivity to warfarin in these patients, VKORC1 was chosen. In order to determine the impact of VKORC1 1173C>T and 3730G>A polymorphisms in warfarin dose variability, a protocol of RFLP based PCR with HinfI and SsiI was used. Polymorphisms of VKORC1 were effective factors in sensitivity to warfarin in the majority of them. However, in some of sensitive patients, there was inconformity of clinical phenotypes with CYP2C9 and VKORC1 genotypes. In conclusion, our findings suggest that CYP2C9 and VKORC1 are not the only effective factors in sensitivity to warfarin and more studies are necessary for investigation of sensitivity reasons in these patients.

Fulltext PDF Fulltext HTML

How to cite this article
Z. Kianmehr, P. Ghadam, S. Sadrai, B. Kazemi and R.A. Sharifian, 2010. VKORC1 Gene Analysis of Some Iranian Sensitive Patients to Warfarin. Pakistan Journal of Biological Sciences, 13: 906-910.

Keywords: RFLP based PCR, Warfarin, pharmacogenetic, anticoagulant drug, Warfarin sensitivity and VKORC1

INTRODUCTION

Warfarin is currently the most widely used oral anticoagulant drug for the prevention and treatment of patients with arterial and venous thromboembolic disorders (Hirsh et al., 2001). However, the use of this drug is accompanied by considerable problems because of the high interindividual variability, as well as intraindividual variability in dose requirement (Takahashi et al., 2003). To achieve and maintain an optimal warfarin dose, the prothrombin time and the International Normalized Ratio (INR) are monitored and doses are adjusted to maintain the patient’s INR within a narrow therapeutic range. The target INR depends on the indication of warfarin treatment. For most indications, the ideal INR value lies between 2.0 and 3.0 (Horton and Bushwick, 1999). The large variability in warfarin response is multifactorial.

Polymorphisms in the gene encoding the cytochrome P-450 2C9 enzyme (CYP2C9) are known to contribute to variability in sensitivity to warfarin (Kim et al., 2009). CYP2C9 is the enzyme primarily responsible for the metabolic clearance of the S-enantiomer of warfarin. A number of polymorphisms in CYP2C9 have been identified, but the most important are CYP2C9*2 (R144C) and CYP2C9*3 (I359L). However, allelic variants of CYP2C9 cannot fully explain the large interindividual and interethnic differences in warfarin dose requirements, suggesting that additional factor(s) may contribute to this variability (Takahashi et al., 2004).

The presence of polymorphisms in the Vitamin K epoxide reductase subunit 1 gene (VKORC1) has been recently identified as another cause of variability in the response to warfarin in many populations (Kim et al., 2009). VKORC1 recycles vitamin K epoxide to the reduced form of vitamin K, an essential cofactor in the formation of the active clotting factors II, VII, IX and X through γ-glutamyl carboxylation .Warfarin inhibits VKORC1 activity by reducing the regeneration of vitamin K and thus exerting its anticoagulation effect (Cain et al., 1997). Several studies have been shown association between VKORC1 polymorphisms and reduction of warfarin dose requirement and warfarin sensitivity (D’Andrea et al., 2005; Geisen et al., 2005; Yuan et al., 2005; Lee et al., 2006). To date, numerous Single Nucleotide Polymorphisms (SNPs) have been identified in the VKORC1 gene. Among these SNPs, two common polymorphisms, a C>T transition at position 1173 (rs9934438) in intron 1 and 3730G>A transition in the 3'-untranslated region [UTR] (rs7294) in VKORC1 gene, affect the interindividual variability of warfarin dose (D’Andrea et al., 2005). In some of populations the SNP 1173C>T has been reported to be associated with the low dose warfarin phenotype (Limdi et al., 2008) and patients carrying at least one 1173T allele have an increased risk of bleeding compared to those with the CC genotype (Reitsma et al., 2005). In addition, it has been shown that the SNP 3730G>A was associated with higher warfarin dose requirement (D’Andrea et al., 2005).

Genetic polymorphisms involved in both pharmacokinetic (e.g., CYP2C9) and pharmacodynamic (e.g., VKORC1) factors. Therefore, appear to interplay in the overall interindividual variability of warfarin doses; moreover, the contribution of each factor may differ among different ethnic populations (Yin and Miyata, 2007).So for the first time in this study, the effect of VKORC1 1173C>T and 3730G>A polymorphism in variability of warfarin requirement in some of Iranian warfarin sensitive patients was investigated.

MATERIALS AND METHODS

This project has been conducted at Alzahra University since 2008.

In this study, 58 treated patients with warfarin were recruited from Imam Khomeini Hospital (Tehran-Iran) for participation in this trial. The study group clinically sensitive patients (22 patients) were selected by participating centers according to the following criteria:

• Adult-patients who need less than 10.5 mg week-1 of warfarin to keep the INR in therapeutic range (INR = two - three)
• Patients who were on usual dose of warfarin (5-15 mg day-1) but they had bleeding or INR>4 either in seven days after cessation of warfarin or three days after receiving 3 mg day-1 vitamin K1 intravenously

The first criterion was chosen from previous reports (Linder, 2001) and the second was chosen by our group while encountered such patients in clinic. The control group (36 adult patients) was randomly selected from patients who took warfarin for various causes and showed normal response to warfarin. In order to determine the impact of 1173C>T and 3730G>A SNPs in VKORC1, a protocol of RFLP (Restriction Fragment Length Polymorphism) based PCR was used. DNA was extracted from whole blood samples using the DNG-PlusTM kit (Fermentas).

Primers 1173F (5'TGACATGGAATCCTGACGTG3') and 1173R (5'GAGCTGACCAAGGGGGAT3' ) for amplification of 361 base pairs (bp) from intron one of VKORC1 gene (D’Andrea et al., 2005), also primers 3730F (5'AGCCTGATGTGGCTCAGTTT3') and 3730R (5'GTGTGGCACATTTGGTCCATT3') for amplification of 226 bp from the 3'UTR of VKORC1 gene were selected (Li et al., 2006). DNA samples were amplified by PCR in a final volume of 15 μL, with 7.5 μL PCR Master Mix (Ampliqon), 0.5 mM each primer, 0.3 μg genomic DNA. Amplification conditions consisted of an initial denaturation of 10 min at 94°C, followed by 30 PCR cycles in 30 sec at 94°C, 30 sec at 58°C and, 90 sec at 72°C with a final extension of 5 min at 72°C. PCR products of these fragments (2 μg from each) were digested with 10 units of Hinf I and SsiI (AciI), respectively in a final volume of 30 μL in the appropriate digestion buffer at 37°C for 16 h. The digested products were visualized on 8% poly acryl amide gels stained with ethidium bromide.

All the Statistical analyses were performed using SPSS for Windows, version 11.5. Multiple comparisons between different CYP2C9 and VKORC1 haplotypes were made using univariate analysis (ANOVA), the unequal variance t-test and Post-Hot tests. Results are presented as Mean±SD unless stated otherwise. A p-value of less than 0.05 was taken as statistically significant.

RESULTS

PCR product of 1173C>T region contained 361 bp. There was one recognition site in position eight for restriction enzyme HinfI in wild type genotype (homozygote CC) so that two fragments (353 and 8 bp) are formed upon HinfI digestion. The 1173T allele created another HinfI recognition site in position 59 and three fragments (310, 43 and 8 bp) in mutant homozygous (TT) and four fragments (353, 310, 43 and 8 bp) in heterozygote genotype (CT) were resulted by HinfI digestion. PCR product of 3730G>A region contain 226 bp. There was one recognition site in position 195 for restriction enzyme SsiI in wild type genotype (homozygote GG) so that two fragments (195 and 31 bp) are formed upon SsiI digestion. In the present of mutation (3730A allele), SsiI has no recognition site and thus one fragment (226 bp) in mutant homozygote (AA) and three fragments (226, 195 and 31 bp) in heterozygote genotype (GA) are formed upon SsiI digestion. There was not wild type genotype (GG) in our samples.

The genotype information was achieved from the band cleavage patterns (Fig. 1, 2). Genotype distributions of CYP2C9 allele variants (*1*1,*1*2, *2*2), 1173C>T and 3730G>A SNPs in VKORC1, mean weekly warfarin dose requirements and blood warfarin concentrations in all patients are summarized in Table 1.

Fig. 1:
Acryl amide gel electrophoresis of PCR-RFLP in 1173C>T region with restriction enzyme HinfI. Lane 1: DNA ladder molecular size marker (100 bp), Lanes 2, 3, 4: 1173 TT, Lanes 5, 6: 1173 CT, Lanes 7, 8, 9: 1173 CC

Fig. 2:
Acryl amide gel electrophoresis of PCR-RFLP in 3730G>A region with restriction enzyme SsiI. Lane1: DNA ladder molecular size marker (100 bp), Lanes 2, 5: 3730 AA , Lanes 3, 4, 6, 7 and 8: 3730 GA

As shown, mean weekly warfarin doses in carriers of CYP2C9*1*2 and *2*2 are significantly lower (p = 0.006) like patients with 1173CT and TT, in contrast to carriers of 3730AA that need higher doses.

Table 1: Relationship between CYP2C9 and VKORC1 genotype distributions and pharmacokinetics of warfarin
n: No. of patients, INR: International Normalized Ratio, Conc: Concentration. A p-value of less than 0.05 was taken as statistically significant. *In literatures, CYP2C9 genotypes are shown by this symbol

Table 2: Relationship between CYP2C9 and VKORC1 genotype distributions and warfarin sensitivity in patients
No. of patients (percent of total sensitive patients), No. of patients (percent of total normal patients)

Mean concentration of warfarin in patients blood with CYP2C9*1*1 is lower than others with *1*2 variant. Mean concentration of warfarin in the blood of TT carriers is lower than CT and CC carriers (Table 1). The frequencies of the allele variants CYP2C9 and 1173C>T and 3730G>A SNPs in VKORC1 gene between sensitive and normal patients were shown in Table 2. There were significant differences (p<0.001) in mean warfarin doses between sensitive and normal patients. According to these results, 68.1 and 81.8% of sensitive patients to warfarin have CYP2C9 variant and VKORC1 1173T allele respectively. The frequency of CYP2C9*2*2 was as expected low (6.9%) whereas the frequency of homozygote for VKORC1 1173TT genotype was 17.2% (Table 2).

DISCUSSION

The use of the same fixed dose of warfarin for all patients is unachievable because the responsiveness of different patients to warfarin is highly variable.

Table 3: Relationship between Clinical phenotype and CYP2C9/VKORC1 genotypes
n: No. of patients

Therefore, some patients require less warfarin dose than others warfarin sensitive patients and some of them need more warfarin dose warfarin resistant patients. In many populations CYP2C9 andVKORC1 polymorphisms are important to sensitivity to warfarin (Yuan et al., 2005; Kirchheiner and Brockmoller, 2005; Scott et al., 2008; Wen et al., 2008).

In our previous studies (Ghadam et al., 2009), all patients that used in this study were genotyped for CYP2C9*2 and *3 and in another study the concentration of warfarin in the patient's blood was determined by HPLC (Sadrai et al., 2008). In these population, there were sensitive patients but with wild type CYP2C9 genotype (*1*1). This study was designed to investigate the effect of VKORC1 gene polymorphisms and their relationship to warfarin dose and sensitivity to warfarin in these Iranian warfarin sensitive patients with CYP2C9 *1*1. As it was shown in Table 3, on the basis of CYP2C9 genotype and clinical phenotype, a total of 58 warfarin treated patients were divided in four different groups that genotyped for 1173C>T and 3730G>A SNPs in VKORC1 gene. Consist to the previously published observations (Aithal et al., 1999; Henne et al., 1998; Kamali et al., 2004) our results showed that, majority of sensitive patients have mutation in CYP2C9. Also like studies Takahashi et al. (2006) and Osman et al. (2006) studies our findings confirmed that VKORC1 polymorphism in 1173C>T is effective factor in sensitivity to warfarin in the majority of sensitive patients. But, in contrast to the previous findings which showed that the SNP 3730G>A was associated with higher warfarin dose requirement (D’Andrea et al., 2005) in this study, the patients with SNP 3730G>A need normal or even lower level of warfarin.

Therefore, the VKORC1 1173T allele accounts for low dosage requirements of most patients with CYP2C9 *1*1. However, in some sensitive patients with wild type CYP2C9, there was not mutation in 1173 position of VKORC1. This means that these polymorphisms in CYP2C9 and VKORC1 are not the only effective factors in sensitivity to warfarin, so more investigations should be done in the Iranian patients who have normal CYP2C9 and VKORC1 genotypes but with sensitivity to warfarin until recognized the cause(s) of their sensitivity.

ACKNOWLEDGMENTS

The Vice Chancellor for Research of Alzahra University supported this study. The authors wish to thank Imam Khomeini hospital, Cellular and Molecular Biology Research Center of Shahid Beheshti University, M.C and the Biopharmacutics and Pharmacokinetics Laboratory of Tehran University of Medical Sciences.

REFERENCES

  • Aithal, G.P., C.P. Day, P.J. Kesteven and A.K. Daly, 1999. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet, 353: 717-719.
    PubMed    


  • Cain, D., S.M. Hutson and R. Wallin, 1997. Assembly of the warfarin-sensitive vitamin K 2,3-epoxide reductase enzyme complex in the endoplasmic reticulum membrane. J. Biol. Chem., 272: 29068-29075.
    PubMed    


  • D'Andrea, G., R.L. D`Ambrosio, P. di Perna, M. Chetta and R. Santacroce et al., 2005. A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood, 105: 645-649.
    CrossRef    PubMed    Direct Link    


  • Geisen, C., M. Watzka, K. Sittinger, M. Steffens and L. Daugela et al., 2005. VKORC1 haplotypes and their impact on the inter-individual and inter-ethnical variability of oral anticoagulation. Thromb. Haemost., 94: 773-779.
    CrossRef    PubMed    Direct Link    


  • Ghadam, P., R. Sharifian, Z.J. Farsangi, Z. Kianmehr and M. Lak, 2009. CYP2C9 gene analysis of some Iranian hypersensitive patients to warfarin. Pak. J. Biol. Sci., 12: 1160-1163.
    CrossRef    PubMed    Direct Link    


  • Henne, K.R., A. Gaedigk, G. Gupta, J. Steven Leeder and A.E. Rettie, 1998. Chiral phase analysis of warfarin enantiomers in patient plasma in relation to CYP2C9 genotype. J. Chromatogr. B Biomed. Sci. Applied, 710: 143-148.
    PubMed    


  • Hirsh, J., J.E. Dalen, D.R. Anderson, L. Poller, H. Bussey, J. Ansell and D. Deykin, 2001. Oral anticoagulants: Mechanism of action, clinical effectiveness and optimal therapeutic range. J. Am. Chest Phys., 119: 8S-21S.
    Direct Link    


  • Horton, J.D. and B.M. Bushwick, 1999. Warfarin therapy: Evolving strategies in anticoagulation. Am. Fam Physician., 3: 635-646.
    PubMed    


  • Kamali, F., T.I. Khan, B.P. King, R. Frearson and P. Kesteven et al., 2004. Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin. Clinical. Pharmacol. Therapeutics., 75: 204-212.
    PubMed    


  • Kim, H.S., S.S. Lee, M. Oh, Y.J. Jang and E.Y. Kim et al., 2009. Effect of CYP2C9 and VKORC1 genotypes on early-phase and steady-state warfarin dosing in Korean patients with mechanical heart valve replacement. Pharmacogenetics Genomics., 19: 103-112.
    PubMed    


  • Kirchheiner, J. and J. Brockmoller, 2005. Clinical consequences of cytochrome P450 2C9 polymorphisms. Clin. Pharmacol. Therapeutics, 77: 1-16.
    CrossRef    PubMed    


  • Lee, S.C., S.S. Ng, J. Oldenburg, P.Y. Chong and S. Rost et al., 2006. Interethnic variability of warfarin maintenance requirement is explained by VKORC1 genotype in an Asian population. Clin. Pharmacol. Ther., 79: 197-205.
    CrossRef    PubMed    Direct Link    


  • Li, T., L.A. Lange, X. Li, L. Susswein and B. Bryant et al., 2006. Polymorphisms in the VKORC1 gene are strongly associated with warfarin dosage requirements in patients receiving anticoagulation. J. Med. Genet., 43: 740-744.
    CrossRef    PubMed    


  • Limdi, N.A., D.K. Arnett, J.A. Goldstein, T.M. Beasley and M.J. Rieder et al., 2008. Influence of CYP2C9 and VKORC1 polymorphisms on warfarin dose, anticoagulation attainment and maintenance among European American and African Americans. Pharmacogenomics, 9: 511-526.
    CrossRef    PubMed    


  • Linder, M.W., 2001. Genetic mechanisms for hypersensitivity and resistance to the anticoagulant Warfarin. Clin. Chim. Acta, 308: 9-15.
    CrossRef    PubMed    Direct Link    


  • Osman, A., C. Enstrom, K. Arbring, P. Soderkvist and T.L. Lindahl, 2006. Main haplotypes and mutational analysis of vitamin K epoxide reductase (VKORC1) in a Swedish population: A retrospective analysis of case records. J. Thromb. Haemost., 4: 1723-1729.
    PubMed    


  • Reitsma, P.H., J.F. van der Heijden, A.P. Groot, F.R. Rosendaal and H.R. Buller, 2005. A C1173T dimorphism in the VKORC1 gene determines coumarin sensitivity and bleeding risk. PLoS Med., 2: e312-e312.
    CrossRef    PubMed    


  • Sadrai, S., P. Ghadam, R. Sharifian, E. Nematipour, Z. Kianmehr and S. Shahriari, 2008. Pharmacokinetic analysis of warfarin in iranian warfarin sensitive patients. Int. J. Pharmacol., 4: 149-152.
    CrossRef    Direct Link    


  • Scott, S.A., L. Edelmann, R. Kornreich and R.J. Desnick, 2008. Warfarin Pharmacogenetics: CYP2C9 and VKORC1 genotypes predict different sensitivity and resistance frequencies in the Ashkenazi and Sephardi Jewish populations. Am. J. Human Genet., 82: 495-500.
    PubMed    


  • Takahashi, H., G.R. Wilkinson, Y. Caraco, M. Muszkat and R.B. Kim et al., 2003. Population differences in S-warfarin metabolism between CYP2C9 genotype-matched Caucasian and Japanese patients. J. Clin. Pharmacol. Ther., 73: 253-263.
    CrossRef    PubMed    Direct Link    


  • Takahashi, H., G.R. Wilkinson, R. Padrini and H. Echizen, 2004. CYP2C9 and oral anticoagulation therapy with acenocoumarol and warfarin: Similarities yet differences. Clin. Pharmacol. Ther., 75: 376-380.
    PubMed    


  • Takahashi, H., G.R. Wilkinson, E.A. Nutescu, T. Morita and M.D. Ritchie et al., 2006. Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans. Pharmacogenet Genomics, 16: 101-110.
    PubMed    


  • Wen, M.S., M.T.M. Lee, J.J. Chen, H.P. Chuang and L.S. Lu et al., 2008. Prospective study of warfarin dosage requirements based on CYP2C9 and VKORC1 genotypes. Clin. Pharmacol. Therapeutics, 81: 83-89.
    PubMed    


  • Yin, T. and T. Miyata, 2007. Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC1: Rationale and perspectives. Thromb. Res., 120: 1-10.
    PubMed    


  • Yuan, H.Y., J.J. Chen, M.T. Lee, J.C. Wung, Y.F. Chen and M.J. Charng, 2005. A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity. Hum. Mol. Genet., 14: 1745-1751.
    CrossRef    PubMed    Direct Link    

  • © Science Alert. All Rights Reserved